Vertex Pharmaceuticals Up Over 5%, on Pace for Largest Percent Increase Since November 2024 -- Data Talk

Dow Jones12-04

Vertex Pharmaceuticals Incorporated $(VRTX)$ is currently at $457.50, up $24.36 or 5.62%

 

--Would be highest close since Aug. 4, 2025, when it closed at $472.27

--On pace for largest percent increase since Nov. 5, 2024, when it rose 5.73%

--Currently up five of the past six days

--Currently up two consecutive days; up 7.5% over this period

--Best two day stretch since the two days ending Dec. 14, 2023, when it rose 13.66%

--Up 13.61% year-to-date; on pace for best year since 2023, when it rose 40.9%

--Down 11.46% from its all-time closing high of $516.74 on Nov. 8, 2024

--Down 1.40% from 52 weeks ago (Dec. 4, 2024), when it closed at $463.98

--Down 10.95% from its 52-week closing high of $513.76 on March 17, 2025

--Up 24.82% from its 52-week closing low of $366.54 on Aug. 8, 2025

--Traded as high as $461.38; highest intraday level since Aug. 4, 2025, when it hit $473.37

--Up 6.52% at today's intraday high; largest intraday percent increase since Jan. 31, 2025, when it rose as much as 7.67%

--Third best performer in the S&P 500 today

--Third best performer in the Nasdaq 100 today

 

All data as of 12:00:02 PM ET

 

Source: Dow Jones Market Data, FactSet

 

(END) Dow Jones Newswires

December 03, 2025 12:03 ET (17:03 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment